Medicinal Product 
End-to-end support from experienced Regulatory experts.

Pharma Regulatory Services in the European Union (EU) - Overview

The European Union operates a harmonized regulatory framework for human medicines, combining EU-wide authorization routes with coordinated national procedures. Marketing authorizations are granted through the European Medicines Agency (EMA) and National Competent Authorities (NCAs), depending on product type, legal basis, and market strategy.

Applicants may pursue EU-wide approval via the Centralized Procedure (CP) or follow nationally coordinated routes such as the Decentralized Procedure (DCP), Mutual Recognition Procedure (MRP), or purely National Procedures (NP). Selecting the optimal pathway requires careful consideration of eligibility, regulatory risk, approval timelines, and lifecycle implications across Member States.

Under the Centralized Procedure, a single Marketing Authorization Application (MAA) is assessed by EMA’s Committee for Medicinal Products for Human Use (CHMP), resulting in a European Commission decision that is valid across the EU and EEA. In contrast, DCP, MRP, and national pathways are coordinated through NCAs under CMDh frameworks, with procedural rules defined by Directive 2001/83/EC and related EU legislation.

Freyr supports sponsors across all EU authorization routes, aligning regulatory strategy, dossier preparation, and submission execution to achieve predictable approvals and sustainable lifecycle compliance.

EU authorization routes

  • Centralized Procedure (CP):
    A single EU/EEA authorization following EMA scientific assessment and a European Commission decision, applicable where the mandatory scope is met or eligibility is granted.
  • Decentralized Procedure (DCP):
    First-time marketing authorizations in multiple Member States, coordinated by a Reference Member State (RMS) with agreement from Concerned Member States (CMS) under CMDh.
  • Mutual Recognition Procedure (MRP):
    Extension of an existing national authorization to additional Member States through coordinated recognition.
  • National Procedure (NP):
    Single-country authorization managed directly by the relevant NCA for products outside EU-wide or multi-state strategies.

Current complexities

  • Centralized Procedure submissions must be transmitted through EMA-mandated electronic channels (eSubmission Gateway or Web Client), including lifecycle sequences and ASMF submissions.
  • DCP, MRP, and National Procedure submissions are handled via NCA-managed electronic systems, coordinated under HMA/CMDh procedural frameworks rather than EMA platforms such as IRIS for dossier submission.
  • Clinical Trial Applications are governed by the EU Clinical Trials Regulation (EU) No. 536/2014, with CTIS serving as the single entry point for new trials across Member States.
  • EMA’s transition to SPOR-enabled DADI web forms is modernizing EU application data management, replacing legacy PDF application forms and increasing the importance of accurate master data alignment (RMS/OMS).

 

Send Us a Request 

Freyr Expertise – Pharma Regulatory Services in the EU

  • End-to-end support for compiling, publishing, and submitting eCTD dossiers for MAAs (CP, DCP, MRP, NP), variations (Type IA/IB/II), renewals, and lifecycle activities via EMA and NCA submission channels.
  • EU route-to-market strategy, including assessment of CP scope and eligibility, RMS selection for DCP, sequencing of approvals, and selection of appropriate legal bases (generics, hybrids, biosimilars, well-established use, informed consent).
  • Clinical Trial Application management under CTR 536/2014, covering CTIS planning, dossier authoring, RFI responses, and transition of legacy trials into the EU framework.
  • Management of EMA scientific and regulatory procedures via IRIS, including scientific advice, protocol assistance, orphan designation, PIP activities, and PRIME eligibility coordination.
  • Planning and coordination of Active Substance Master File (ASMF) submissions, ensuring compliant electronic pathways for centralized and multi-state procedures.
  • Module 1 authoring and EU labeling support, including SmPC, PL, and packaging texts aligned with EMA/NCA templates, national blue box requirements, and multilingual translation and mock-up management.
  • Gap analysis of quality, non-clinical, and clinical modules against EU and ICH expectations, with risk-based remediation strategies tailored to CP versus DCP/MRP pathways.
  • Preparation for DADI and eAF submissions, including SPOR (RMS/OMS) data readiness and alignment with EMA eSubmission requirements.
  • Management of centralized assessment milestones (e.g., Day 120/180 Lists of Questions and Outstanding Issues), including coordinated responses and clock-stop planning.
  • Post-approval lifecycle management across centrally and nationally authorized products, covering variations, renewals, and CMDh-aligned lifecycle maintenance to ensure ongoing compliance and continuity of supply.

Freyr delivers integrated EU regulatory strategy and operations across the product lifecycle—from clinical trial planning and CTIS submissions, through MAA strategy and execution, to post-approval lifecycle maintenance. We align regulatory pathways, dossiers, and submission timelines with EMA and CMDh requirements to enable predictable approvals, efficient market entry, and sustained compliance across the EU.

Send us a Request